Stocks of Eli Lilly and Company (NYSE:LLY) traded higher last session on Wall Street, down -1.21% to $591.61.
According to the data, Eli Lilly and Company (NYSE:LLY) has 28 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $640.00 and a low of $340.00, we find $600.00. Given the previous closing price of $598.88, this indicates a potential upside of 0.19 percent. LLY stock price is now 16.99% away from the 50-day moving average and 44.64% away from the 200-day moving average. The market capitalization of the company currently stands at $548.94B.
A total of 4 analysts have issued a hold rating and 20 have given it a buy rating. Brokers who have rated the stock have averaged $571.51 as their price target over the next twelve months.
With the price target enhanced from $408 to $615, Jefferies Upgraded its rating from Hold to Buy for Eli Lilly and Company (NYSE: LLY).
In other news, Weems Alonzo, EVP, ERM & CECO sold 1,148 shares of the company’s stock on Sep 12. The stock was sold for $678,445 at an average price of $590.98. Upon completion of the transaction, the EVP, ERM & CECO now directly owns 7,760 shares in the company, valued at $4.59 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 07, 10% Owner LILLY ENDOWMENT INC sold 210,000 shares of the business’s stock. A total of $119,995,275 was realized by selling the stock at an average price of $571.41. This leaves the insider owning 99,983,810 shares of the company worth $59.15 billion. Insiders disposed of 3,262,211 shares of company stock worth roughly $1.93 billion over the past 1 year. A total of 10.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LLY stock. A new stake in Eli Lilly and Company shares was purchased by TIGER GLOBAL MANAGEMENT LLC during the first quarter worth $428,385,000. WINSLOW CAPITAL MANAGEMENT, LLC invested $287,149,000 in shares of LLY during the first quarter. In the first quarter, UNISUPER MANAGEMENT PTY LTD acquired a new stake in Eli Lilly and Company valued at approximately $146,761,000. COATUE MANAGEMENT LLC acquired a new stake in LLY for approximately $102,890,000. AVIDITY PARTNERS MANAGEMENT LP purchased a new stake in LLY valued at around $78,684,000 in the second quarter. In total, there are 3,403 active investors with 84.80% ownership of the company’s stock.
Thursday’s opening bell rang with an opening price of $599.24 for Eli Lilly and Company (NYSE: LLY). During the past 12 months, Eli Lilly and Company has had a low of $296.32 and a high of $601.13. As of last week, the company has a debt-to-equity ratio of 1.70, a current ratio of 1.10, and a quick ratio of 0.90. According to the stock market information, the enterprise value for the company is $584.50B, which is based on a 82.19 price-to-earnings ratio, a 3.31 price-to-earnings-growth ratio, and a beta of 0.31. The fifty day moving average price for LLY is $508.21 and a two-hundred day moving average price translates $410.14 for the stock.
The latest earnings results from Eli Lilly and Company (NYSE: LLY) was released for Jun, 2023. The net profit margin was 22.00% and return on equity was 60.50% for LLY. The company reported revenue of $8.31 billion for the quarter, compared to $6.49 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 28.11 percent.
Moreover, the firm recently paid out its quarterly dividend on 09/08/2023. Investors who held shares on 08/15/2023 were paid a $1.13 dividend. On an annualized basis, this represents a $4.52 dividend and a 0.76% percent yield. There was an ex-dividend date of 08/14/2023 for this dividend. In terms of dividend payout ratio, LLY is presently at 58.50%.
Eli Lilly and Company(LLY) Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
